TABLE 2.

Relative levels of total IgG, anti-Gal IgG, and AAL-reactive anti-Gal IgG in patients with limited fibrosis, severe fibrosis, or cirrhosis

Patient groupaFold greater than healthy purchased controlb
Total IgGcAnti-Gal IgGdAAL-reactive anti-Gal IgGe
Experimental control samples1 ± 0.11 ± 0.11 ± 0.1
F1-F21.8 ± 0.12 ± 0.23 ± 0.2
F3-F52.1 ± 0.23.5 ± 0.19 ± 0.2
Cirrhotic2.4 ± 0.13.7 ± 0.115 ± 0.2
  • a Fibrosis staging was based on the Ishak scoring system. Samples were combined for analysis. Ten samples per group were used for analysis. F, fibrosis stage.

  • b All values are provided as relative increases over commercially purchased sera ± standard deviations.

  • c The relative increase in IgG compared to commercially purchased sera.

  • d The relative increase in anti-Gal IgG compared to commercially purchased sera.

  • e The relative increase in AAL-reactive anti-Gal IgG compared to commercially purchased sera.